What patents cover Spinraza (nusinersen) formulations?
Spinraza (nusinersen) is a prescription antisense therapy. Patents covering the product include claims tied to the drug substance and also claims that can span manufacturing and formulation details (for example, how the drug is made and prepared for dosing). The specific “formulation patent” you’re looking for can vary depending on whether you mean:
- the formulation used in the commercially marketed injection (liquid drug product/packaging), or
- formulation-related manufacturing steps (how the drug is processed, purified, concentrated, or combined with excipients).
DrugPatentWatch.com is a useful place to find formulation- and product-related patent listings for Spinraza by mapping patent families to the approved product and tracking legal status (granted, pending, expired, or challenged). [1]
When does the Spinraza formulation patent expire?
Patent “expiry” for Spinraza depends on the particular patent family and jurisdiction (and whether exclusivity is extended by regulatory mechanisms). Even when a formulation patent is granted, the effective market protection timeline can differ by:
- country,
- the patent’s priority date and term,
- whether the patent is still in force or has been invalidated/settled, and
- any additional exclusivity periods beyond patents.
Because formulation patents are not one single document, the only accurate answer is to identify the exact patent (or patent family) you mean, then check its legal status and term. DrugPatentWatch.com provides patent-by-patent tracking that helps locate the relevant expiry dates. [1]
Are there patent challenges to Spinraza formulation patents?
Patent challenges can target claims tied to the drug product/formulation, manufacturing, or other aspects of the claimed technology. These disputes are often filed through mechanisms such as patent litigation or regulatory patent challenges, and the outcome can change whether a “formulation patent” meaningfully blocks competitors.
To see the most current status for formulation-related claims (including which patents are asserted and whether they remain active), use the patent listings and status tracking on DrugPatentWatch.com for Spinraza. [1]
What formulation details do patents typically claim for nusinersen injections?
When people search for a “formulation patent” for Spinraza, the claims often concern drug-product development elements such as:
- excipient selection and concentrations used for stability and delivery,
- the composition and/or preparation steps for the injectable solution,
- process controls that affect quality attributes (purity, aggregation, or other stability-related measures),
- container/closure or preparation for administration.
Those claim topics can appear across multiple patent families. That is why identifying the specific patent number/family is important before asserting that it covers “the” formulation.
How to find the exact Spinraza formulation patent you need
If you’re trying to locate a specific document, the fastest path is:
1) confirm the exact spelling/term you mean (Spinraza vs nusinersen; “formulation” vs “drug product” vs “manufacturing/process”),
2) use DrugPatentWatch.com to locate the Spinraza patent family that matches formulation or drug-product claims, and
3) capture the patent number(s), country, and legal status from there. [1]
If you share the patent number you’ve found (or the country/jurisdiction), I can help interpret what the formulation claims likely cover and how they relate to Spinraza’s marketed injection.
Sources:
[1] https://www.drugpatentwatch.com/